Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
December 2018
79
About the Report
About the Report
Summary
Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company focuses on thrombosis, anesthetics and high potency and cytotoxics therapeutic categories. It also manufactures infant nutritionals and consumer healthcare products in selected territories. Its manufacturing capabilities cover a range of product-types including oral solid dose, semi-solids, liquids, steriles, biological, active pharmaceutical ingredients (APIs) and infant nutritionals. The company has presence in Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.
Aspen Pharmacare Holdings Ltd (APN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Aspen Pharmacare Holdings Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For USD 257 Million 28
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For USD 263 Million 31
Partnerships 33
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33
AstraZeneca Enters into Co-Marketing Agreement with Aspen 34
ANI Pharma Enters into Distribution Agreement with Aspen 35
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36
Navamedic Amends Distribution Agreement With Aspen Pharma 37
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38
Licensing Agreements 39
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39
Aspen Pharma Enters into Licensing Agreement with Starpharma 40
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44
Equity Offering 45
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45
Asset Transactions 47
Endo International Acquires Portfolio of Branded and Generic Products 47
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51
Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 52
Acquisition 53
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For USD 696.5 Million 54
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For USD 18.6 Million 55
Aspen Pharmacare Holdings Ltd-Key Competitors 56
Aspen Pharmacare Holdings Ltd-Key Employees 57
Aspen Pharmacare Holdings Ltd-Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 61
Recent Developments 62
Financial Announcements 62
Mar 08, 2018: Aspen delivers double digit revenue and earnings growth 62
Sep 14, 2017: Aspen increases revenue by 16% to R41.2 billion 65
Mar 09, 2017: Aspen: Unaudited interim financial results for the six months ended 31 December 2016 68
Legal and Regulatory 71
Jun 13, 2017: Aspen: South African Competition Commission Announcement 71
May 15, 2017: Aspen: Opening of European Commission proceedings 72
Apr 24, 2017: Aspen's response to the reported Competition Commission investigation 73
Government and Public Interest 74
May 29, 2017: Aspen Cleared of Alleged Anti-competitive Behavior by DA 74
May 15, 2017: Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines 75
Other Significant Developments 77
Oct 26, 2018: Aspen's participation in the 2018 Investment Conference 77
Mar 01, 2017: Aspen-Trading Statement 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
List of Figure
List of Figures
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For USD 257 Million 28
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For USD 263 Million 31
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33
AstraZeneca Enters into Co-Marketing Agreement with Aspen 34
ANI Pharma Enters into Distribution Agreement with Aspen 35
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36
Navamedic Amends Distribution Agreement With Aspen Pharma 37
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39
Aspen Pharma Enters into Licensing Agreement with Starpharma 40
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45
Endo International Acquires Portfolio of Branded and Generic Products 47
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51
Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 52
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For USD 696.5 Million 54
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For USD 18.6 Million 55
Aspen Pharmacare Holdings Ltd, Key Competitors 56
Aspen Pharmacare Holdings Ltd, Key Employees 57
Aspen Pharmacare Holdings Ltd, Other Locations 58
Aspen Pharmacare Holdings Ltd, Subsidiaries 58
Aspen Pharmacare Holdings Ltd, Joint Venture 61
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.